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Abstract 
 
         Background  BD:   BCL2  family  is  a  large  family  of  apoptosis  regulating  proteins 
consisting of both blockers and promoters of cell death. Immunological processes and a variety 
of cytokines may play a role in pathophysiological process. Defective regulation of programmed 
cell death (apoptosis) also play a role in development of Behcet’s disease  
         Objective: To  investigate the  level of  BCL2  and IL13in  BD and  to determine  their  to 
relation monitory disease activity. 
         Patients and methods: This study was conducted on thirty patients  (15 active and 15 
inactive)  and  15-health  control,  the  activity  of  BD  was  evaluated  according  to  international 
study group for BD disease, using ELISA technique for IL 13 and flow cytometry forBCL2. 
         Results:  Elevated serum levels of IL13 in patient with active BD than inactive and both 
had elevated  levels  than  control(P<  0.01) and  also  the  serum  levels of  Bcl2  was  elevated  in 
patient with active BD than inactive and control(P< 0.01). 
Concolusion: The data suggested that IL13 and BCL2 could be involved in the pathogenesis of 
BD and its serum levels can be used as marker to monitor disease activity. 
 
Introduction       
         
        Behcet’s disease   (BD)  is  an  inflam-
matory  multisystem  disorder  chara-cterized 
by  recurrent  oral    genital  and  aphthous 
ulcers  ,  arthritis,uveitis  and  therombophle-
pitis  that  can  involve  several  organs 
(Emmi et al., 1997). 
         Hulusi  Behcet,  is  Turkish  dermat-
ologist  ,described  the    recurrent  orogenital 
ulceration and  uveitis in1937. The preval-
ence of BD is highest in Japan, south Asia 
,the middle east and southern Europe  .The 
disease is  rare  in northern  Europe  and  the 
United  state  (Jorizzo,1999).Although  the 
etiology  and  the  pathogenesis  of  BD  still 
remain  uncertain,  it  has  been  suggested, 
that  three major pathophosiologic changes, 
neutrophil  hyperfunction,  vasculitis  and 
autoimmune  response  may  be  involved  in 
its  pathogenesis ( Sakane et al.,1997)  
         Recent  studies  have  indicated  that 
cytokine- producing cells play an important 
role  in  the  immunopathogenesis  of  inflam-
mation in BD (Sugi et al., 1998). In part-
icular,  a  divergent  cytokine  production 
profile  of  TH1/TH2  cell  type  is  very 
important  in  the  immune  response 
occurring in BD (Raziuddin et al.,1998) .  
         Programmed cell death (apoptosis) is 
important  in  down-modulation  immune 
response  after  activation  and  proliferation 
of inflammatory cells. It has been suggested 
that dysregulated apoptosis of lymphocytes 
may  be  linked  to  the  development  of 
autoimmune  disease  as  Sjogrens  syndrome 
(Ichikawa  et  al.,1995),  systemic  lupus 
erythematosus  (SLE)(Aringer  et  al.,1991) 
and  rheumatoid  arthritis(RA  )  (Isomaki  et 
al.,1996).  Defective  regulation  of  progra-
mmed  cell  death  (apoptosis)  may  play  a 
role  in  the  development  of  BD  and  the 
protoncogene  Bcl-2  is  involved  in  the 
control  of  apoptosis  in  immunocompetent 
cells (Hamzaoui  et al., 1999).  
         The diagnostic criteria established by 
the  international  study  group  for  Behcet's 
disease  requires  the  presence  of  recurrent 
oral  ulceration  and  two  of  the  following: 
recurrent  genital  ulceration,  eye  lesions, 
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skin lesions and/or a pathergy test. Pathergy 
respone  is  anoduleor  pustule,  3-10mm, 
appearing 24-48 hours after puncture of the 
forearm  Srin  with  sterile  20  gauge  needle. 
(Table 1) 
 
Patients and methods 
 
Patient group:  
         Thirty patients with BD were studied 
(15  active  and15  inactive).The  active 
group,the sex (M/F 13/2) ,aged  (30-41)the 
mean  (40.40  ±  587  ).Inactive  group  15 
patients (M/F 12/3) aged (32-44) The mean 
(41.80 ± 5.89 ) the activity was evaluated 
according  to  international  study  group  of 
Behects  disease.  We  collected  the  patients 
from  out  patient  clinic  of  dermatology 
,internal  medicine  and  ophthalmology  Al 
Zahraa  hospital,  Al-Azhar  university  and 
otherhospitals . 
 
Control group: 
         15  healthy  subjects  (M/F  9/6)  aged 
(22-45)  years,  the  mean  (35.93  ±  1.31  ) 
years were served as control group.  
   
All  patients  and  control  group  were 
subjected to the following: 
         Full  history,  thorough  clinical 
examination, complete blood picture, eryth-
rocyte  sedimentation  rate  (ESR),  fundus 
examination ,serum IL 13 and Bcl2. 
 
Sample collection & storage: 
         A  fresh  peripheral  blood  sample  is 
collected by veni-puncture and divided into 
two  tubes,  one  empty  tube  for  serum 
sample  and  the  other  with  heparin  for 
lymphocyte separation. 
 
Measurement of IL-13:  
         Serum sample was used for estimation 
of  IL–13  using  ELISA  technique  (Bio- 
source international). 
 
Determination of BCL2: 
         Heparin  blood  sample  was  used  for 
separation  of  lymphocyte  by  Ficall-
Hypique  density-gradient  centrifugation  & 
washed twice with PBS at +4
oC. Then add 
20 Ml of Antigen Extraction Agent (AEA) 
for  every  100  Ml  of  cell  suspension  of 
incubate  30  minutes  on  ice  with  the 
occasional  vortexing  then  transfer  extracts 
to micro-centrifuge tubes and centrifuge for 
5 minutes. The samples are now ready for 
analysis  by  Bender  Med  systems  human 
BCL-2 ELISA. 
 
Results 
 
         Thirty  patients  (15  active  and  15 
inactive). Active  patient  with  BD  (male  to 
female  ratio  13/2  (86.87%  -  13.33%)  age 
ranged  (30-
inactive  BD  male  to  female  12/3  (80%-
20%) age  ranged (32-44)  the mean  (41.80 
to female (9-6) age (22-45) the mean (35.93 
 
         Table (4) shows some clinical date of 
some patients with BD. 
         Table  (5)shows  that  Serum  levels  of 
IL13  are  higher  in-patient  with  active  BD 
inactive BD (7.2
significant  (P<  0.01  and  P<  0.01)) 
respectively. Also, it was noted that serum 
IL13  level  in  inactive  group  was 
significantly  higher  than  normal  control 
group (p,<0.01) (figure 2) 
         Serum levels of   BCL2  is higher  in-
patients  with  active  BD  than  inactive  and 
respectively with significance difference(P< 
0.01) for all difference.     
         On  comparing  BCL2  in  active  BD 
with  control  there  were  statistically 
significance (P<0.01). On comparing BCL2 
inactive with control there was statistically 
significance (P< 0.01). Table (6) and figure 
(3). 
         ESR  is  higher  in-patient  with  active 
BD than in-patient with inactive and control 
group.  This  difference  was  statistically 
significant. Table (7) and figure (1). 
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 (Table 1)  
 
Criteria for the diagnosis of Behcet's syndrome 
International study group for Behcet's disease 
In the absence of other clinical explanation, patients must have: 
1-  Recurrent  oral  ulceration:  (Aphthous  or  herpetiform  recurring  at  least  3  times  in  1  year 
period and 2 of the following: 
2-  Recurrent genital ulceration. 
3-  Eye lesion: Anterior or post-uveitis, cells in the vitreous by slit lamp examination or retinal 
vasculitis observed by an ophthalmologist.  
4-  Skin  lesions:  Erythema  nodosum,  pseudo-folliculitis,  papulopustular  lesions  or  acneiform 
nodules in post adolescent patients not on corticosteroids.  
5-  Pathergy, read at 24 – 48 hours. 
(Mouts,1994)   
 
Table (2) shows the sex in patients and control 
 
SEX 
 
 
 
 
Active group 
number 
%  Inactive group 
number 
%  Control group 
number 
% 
 
females  2  13.33  3  20  9  60 
males  13  86.67  12  80  6  40 
total  15  100  15  100  15  100 
 
Table (3) shows the age in patient and control. 
 
  Control group  Active group  T value  P value   
 
    1.86  > 0.05  NS 
Control  Inactive  T value  P value   
    2.42  > 0.05  NS 
Inactive  Active  T value  P value   
    0.65  > 0.05  NS 
 
Table (4):- clinical features of some patients with active Behcet's disease 
 
Patient   Disease  
activity 
Symptoms  
1  Active  Oral  
ulcers 
Genital  
ulcer 
Uveitis     
2  Active  Oral  
ulcers 
Genital  
ulcer 
Uveitis   Arthritis  
3  Active  Oral  
ulcers 
Genital  
ulcer 
Uveitis   EN 
4  Active  Oral  
ulcers 
Genital  
ulcer 
   Pulmonary  
5  Active  Oral  
ulcers 
        
6  Partial 
remission 
           
7  Active  Oral  
ulcers 
Genital  
ulcer 
   Acneiform  
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Table (5) shows the serum level of IL-13 in patients and control group. 
 
IL-   Control  Active  T value  P value  Significance 
 
    18.80  < 0.01  HS 
Control  Inactive   T value  P value  Significance 
    4.77  < 0.05  S 
Inactive   Active  T value  P value  Significance 
7.2     17.37  < 0.01  HS 
 
Table (6) shows the serum level of BCL2 in patients and control group 
 
  Control  Active  T value  P value  Significance 
 
    17.16  < 0.01  HS 
Control  Inactive   T value  P value  Significance 
    7.87  < 0.01  HS 
Inactive   Active  T value  P value  Significance 
11.16    13.57  < 0.01  HS 
 
Table (7) shows the ESR in patient and control. 
 
  Control  Active  T value  P value    
 
13.07 
3.01  13.00 
20.19  < 0.01  HS 
Control  Inactive   T value  P value    
3.01  5.37 
6.66  < 0.01  HS 
Inactive   Active  T value  P value    
5.37  13.00 
16.23  < 0.01  HS 
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Discussion        
      
         Bechet's is a polysymptomatic disease, 
as  a  result  of  recurrent  systemic  vasculitis 
with  choronic  course    and  unknown 
acetiology  (Emmi  et  al.,  1997).  Several 
organs  or  systems  can  be  involved  and  the 
symptomatology and severity depend on the 
system  affected,  The  main  clinical  features 
are:  oral  aphthous,  genital  ulcers,  ocular 
lesion,skin  lesion,  arthritis,central  nervous 
system  affection,  vasculitis  and  other  less 
frequent  findings  such    as  pulmonary 
manifestation  (Jorizzo,1999).  Increasing 
evidences  indicate  that  immunological 
processes  and  a  variety  of  cytokines  may 
contribute to the pathophysiological  process 
in BD (Sakane et al.,1997).      
         Recently  it  was  reported  that  patients 
with BD have a dysregulation of programmed 
cell death (Hamzoui et al.,1998).  BCL2 is a 
proto-oncogene  that  regulates  apoptosis  of 
several cell types, BCL2 plays a role in the 
maintenance  of  the  immune  system,  since 
inactivation  of  BCL2  in  mice  leads  to  the 
disappearance  of  the  lymphoid  system 
(Nakayama and Neghishi,1993). Lymphocyte 
activation  in  active  BD  was  increased,  in 
particular  in  the  inflammatory  sites 
(Hamzaoui et al.,1999). So it is possible that 
the  expression  of  apoptosis-regulating 
proteins, like BCL2, is dysregulated in these 
lymphocytes. 
         In our study we found that the serum 
level  of  IL13  was  significantly  higher  in 
active BD than inactive and both had higher 
level than control group . 
         These  results  are  agreement  with  that 
of Razidudin et al., ( 1998), AL-dalaam et  al 
,1998),  andAridogam  et  al  (2oo3)  who 
reported  that  serum  IL13  level  were  higher 
in patient with active BD than inactive and 
control.  In  contrast  to  these  results  two 
studies  were  done  by  Lehner,  (1999)  and 
Mantas et al., ( 1999  ) reported that there is 
no  statistically  significance  difference  
between BD patients and controls as regard 
serum level of IL13. 
         We have found that the serum levels of 
BCL2 was higher in patient with active BD 
than inactive and both had higher levels than 
control.  These  results  agree  with  data  done 
by Hamzaoui et al. ( 1996) and Hamzaoui  et 
al.  (1999)  and  also  other  data  done  by 
Isömak, ( 1996) who reported that  increased 
expression  of  Bcl2  in  BDand  SLE.    The 
possible explanation for the increased BcL2 
expression  in  the  peripheral  blood  and 
inflammatory  sites  in  BD  disease  was  the 
increased  in  production  of  IL2  (Hamzaoui 
and  Ayed,1990),  because  IL2  has  been 
shown to increase BcL2 expression in active 
T-cells (Deng and Podak,1993) .  
         The increased BcL2 protein expression 
in active BD is non specific for the disease 
and may be explained at least in part by the 
increased  in  vivo  activation  levels  or 
presence of autoimmune vasculitis combined 
with in vivo inducation by aetiopathological 
agents. These may play an important role in 
the  chronic  inflammation  in  BD(Hamzaoui  
et al.,1998). 
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ا يىتسم ديدحت ﻹ  هيكىلرتو 31  ل س ب و 2   تسهب ًضرم ًف  
 
د  / يدمح ًهو
*   -   د / شيورد ًلع دمحم ناىح
* *   -   د  / مج ةليسو ًسىم ةع
***   -   د  /
ملاظ رحس
*  
ا ميناحرنا ىسق ﻹ حيكينيهك
*   حيهسانرنا ً حيدهجنا ضازيلأا ىسق ً
**   حياعنا حنطاثنا ىسق ً
**   *  
 
 
          ا ضازيلأا ني دسيت ضزي دعي ﻹ  ً اعي ىسجنا ني جزيجأ جدع ةيصذ َرنا حيتايرن
ً حيهسانرنا ءاضعلأا ً ىفنات جرزكري خاحزقذ دٌجٌت زيًري ﺇ ت خاتايرن  دق ً نيعنا ً مصافًنا
 لدعي ديدحذ َهع حساردنا هذى دياق  نيكٌنزينلأا 31  ل س ب ً 2   َف    ودنا   ن دسيت َضزً  
 ٍدي ً ﺇ ا  ي اشرنا داعت  انب ً وايدع ناي ضزاًنا طااشنت ىيطاثذر ﻹ  ً َاضزًهن َاكينيهك
 لداعي ياافذرا َانا حاساردنا دهاصٌذ داق ً نياع يااق  احف ماًع ً ةيسزرنا حعزس سايق
ا ﻹ  نيكٌنزين 31 ب ً    ل س 2   َف   حعًٌجي   دسيت َضزي    َضزي حعًٌجًت حنراقي ظشننا
حطتاضنا حعًٌجًنا ً ظشن زيغنا دسيت .  
 
 
 
 